Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · IEX Real-Time Price · USD
27.65
-0.20 (-0.72%)
Jul 26, 2024, 4:00 PM EDT - Market closed
Myriad Genetics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year Ending | TTM | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Jun 30, 2020 | 2019 - 2014 |
|---|---|---|---|---|---|---|---|
| Revenue | 774.2 | 753.2 | 678.4 | 690.6 | 557 | 638.6 | Upgrade
|
| Revenue Growth (YoY) | 11.44% | 11.03% | -1.77% | 23.99% | -12.78% | -24.97% | Upgrade
|
| Cost of Revenue | 241.6 | 236.2 | 202 | 197.6 | 178.2 | 186.1 | Upgrade
|
| Gross Profit | 532.6 | 517 | 476.4 | 493 | 378.8 | 452.5 | Upgrade
|
| Selling, General & Admin | 561.8 | 567.2 | 526.7 | 537.8 | 500.7 | 507.3 | Upgrade
|
| Research & Development | 91.1 | 88.7 | 85.4 | 81.9 | 72.9 | 77.2 | Upgrade
|
| Operating Expenses | 652.9 | 655.9 | 612.1 | 619.7 | 573.6 | 584.5 | Upgrade
|
| Operating Income | -120.3 | -138.9 | -135.7 | -126.7 | -194.8 | -132 | Upgrade
|
| Interest Expense | -2.9 | -2.9 | -3.2 | -6.6 | -11.2 | -10.8 | Upgrade
|
| Interest & Investment Income | 2.4 | 2.5 | 2.6 | 0.7 | 2 | 3 | Upgrade
|
| Currency Exchange Gain (Loss) | -3.4 | -3.4 | 0.2 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 3 | 0.5 | 0.4 | -0.6 | 15.3 | 0.6 | Upgrade
|
| EBT Excluding Unusual Items | -121.2 | -142.2 | -135.7 | -133.2 | -188.7 | -139.2 | Upgrade
|
| Merger & Restructuring Charges | 5.7 | - | - | - | - | - | Upgrade
|
| Impairment of Goodwill | - | - | - | -1.8 | -90.4 | -99.7 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1.5 | -1.5 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 151.6 | - | 1 | Upgrade
|
| Asset Writedown | -5.7 | -5.7 | -16.9 | - | -8 | - | Upgrade
|
| Legal Settlements | -112.8 | -112.8 | - | -62 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | -11.7 | 3.4 | 14.6 | Upgrade
|
| Pretax Income | -235.5 | -262.2 | -140.6 | -57.1 | -283.7 | -223.3 | Upgrade
|
| Income Tax Expense | -0.9 | 1.1 | -28.6 | -29.9 | -59.9 | -23.7 | Upgrade
|
| Earnings From Continuing Operations | -234.6 | -263.3 | -112 | -27.2 | -223.8 | -199.6 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | 0.1 | 0.1 | Upgrade
|
| Net Income | -234.6 | -263.3 | -112 | -27.2 | -223.7 | -199.5 | Upgrade
|
| Net Income to Common | -234.6 | -263.3 | -112 | -27.2 | -223.7 | -199.5 | Upgrade
|
| Shares Outstanding (Basic) | 85 | 83 | 81 | 78 | 75 | 74 | Upgrade
|
| Shares Outstanding (Diluted) | 85 | 83 | 81 | 78 | 75 | 74 | Upgrade
|
| Shares Change (YoY) | 5.01% | 2.73% | 3.33% | 4.31% | 0.64% | -2.24% | Upgrade
|
| EPS (Basic) | -2.76 | -3.18 | -1.39 | -0.35 | -2.99 | -2.69 | Upgrade
|
| EPS (Diluted) | -2.77 | -3.18 | -1.39 | -0.35 | -2.99 | -2.69 | Upgrade
|
| Free Cash Flow | -142.7 | -174.1 | -151.6 | 0.6 | -40.1 | 50.5 | Upgrade
|
| Free Cash Flow Per Share | -1.68 | -2.10 | -1.88 | 0.01 | -0.54 | 0.68 | Upgrade
|
| Gross Margin | 68.79% | 68.64% | 70.22% | 71.39% | 68.01% | 70.86% | Upgrade
|
| Operating Margin | -15.54% | -18.44% | -20.00% | -18.35% | -34.97% | -20.67% | Upgrade
|
| Profit Margin | -30.30% | -34.96% | -16.51% | -3.94% | -40.16% | -31.24% | Upgrade
|
| Free Cash Flow Margin | -18.43% | -23.11% | -22.35% | 0.09% | -7.20% | 7.91% | Upgrade
|
| EBITDA | -67.8 | -82.7 | -83 | -63.9 | -123.4 | -60 | Upgrade
|
| EBITDA Margin | -8.76% | -10.98% | -12.23% | -9.25% | -22.15% | -9.40% | Upgrade
|
| D&A For EBITDA | 52.5 | 56.2 | 52.7 | 62.8 | 71.4 | 72 | Upgrade
|
| EBIT | -120.3 | -138.9 | -135.7 | -126.7 | -194.8 | -132 | Upgrade
|
| EBIT Margin | -15.54% | -18.44% | -20.00% | -18.35% | -34.97% | -20.67% | Upgrade
|
| Revenue as Reported | 753.2 | 753.2 | 678.4 | 690.6 | 557 | 638.6 | Upgrade
|
Source: S&P Capital IQ. Standard template.